Short Interest in Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Declines By 48.4%

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) was the recipient of a significant decline in short interest during the month of March. As of March 13th, there was short interest totaling 9,838 shares, a decline of 48.4% from the February 26th total of 19,055 shares. Based on an average daily volume of 10,987 shares, the short-interest ratio is currently 0.9 days. Currently, 0.2% of the shares of the company are short sold.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Citadel Advisors LLC bought a new position in shares of Alterity Therapeutics in the third quarter worth about $83,000. HB Wealth Management LLC acquired a new stake in shares of Alterity Therapeutics in the 3rd quarter valued at approximately $220,000. Greenleaf Trust grew its holdings in shares of Alterity Therapeutics by 88.2% during the 3rd quarter. Greenleaf Trust now owns 32,000 shares of the company’s stock valued at $120,000 after purchasing an additional 15,000 shares during the last quarter. Finally, Twin Lakes Capital Management LLC increased its position in Alterity Therapeutics by 2,250.3% during the 3rd quarter. Twin Lakes Capital Management LLC now owns 139,258 shares of the company’s stock worth $524,000 after purchasing an additional 133,333 shares in the last quarter. Institutional investors and hedge funds own 2.14% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on ATHE shares. Weiss Ratings restated a “sell (e+)” rating on shares of Alterity Therapeutics in a research note on Wednesday, January 21st. Zacks Research raised shares of Alterity Therapeutics to a “hold” rating in a report on Thursday, February 12th. Finally, Canaccord Genuity Group started coverage on shares of Alterity Therapeutics in a research report on Wednesday, December 17th. They set a “speculative buy” rating for the company. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Alterity Therapeutics has an average rating of “Hold”.

Alterity Therapeutics Trading Up 2.4%

NASDAQ ATHE opened at $3.41 on Thursday. Alterity Therapeutics has a 1 year low of $2.52 and a 1 year high of $7.00. The firm’s 50 day simple moving average is $3.41 and its 200 day simple moving average is $3.71.

Alterity Therapeutics (NASDAQ:ATHE) last issued its earnings results on Friday, January 30th. The company reported ($0.18) earnings per share for the quarter. Analysts anticipate that Alterity Therapeutics will post -0.34 earnings per share for the current year.

About Alterity Therapeutics

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.